Evidence map›Paper›PMID 33540053›Full record

ArticleNeuroscience2021

Silencing Epidermal Growth Factor Receptor in Hypothalamic Paraventricular Nucleus Reduces Extracellular Signal-regulated Kinase 1 and 2 Signaling and Sympathetic Excitation in Heart Failure Rats.

Yang Yu, Shun-Guang Wei, Robert M Weiss, Robert B Felder

Abstract read
In one paragraph

Article in Neuroscience, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Review
  2. Review
  3. Article
  4. Article
  5. Angiotensin II inhibits the A-type KAmerican journal of physiology. Regulatory, integrative and comparative physiology · 2022
    Article
  6. Article
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Yang YuDepartment of Internal Medicine, Roy J and Lucille A Carver College of Medicine, University of Iowa, Iowa City, IA, USA.
Shun-Guang WeiDepartment of Internal Medicine, Roy J and Lucille A Carver College of Medicine, University of Iowa, Iowa City, IA, USA.
Robert M WeissDepartment of Internal Medicine, Roy J and Lucille A Carver College of Medicine, University of Iowa, Iowa City, IA, USA.
Robert B FelderDepartment of Internal Medicine, Roy J and Lucille A Carver College of Medicine, University of Iowa, Iowa City, IA, USA; VA Medical Center, Iowa City, IA, USA. Electronic address: robert-felder@uiowa.edu.

Funding

Propagation and Resolution of Injury in Calcific Aortic Valve DiseaseR01HL142935 · NHLBI · UNIVERSITY OF IOWA · PI WEISS, ROBERT M · 2018 to 2022
$2.3M
Brain ERK1/2 Signaling and Sympathetic Excitation in Heart FailureR01HL136149 · NHLBI · UNIVERSITY OF IOWA · PI FELDER, ROBERT B · 2017 to 2020
$2.1M
Targeting TACE, a novel approach to the treatment of sympathetic excitation in heart failure.R01HL139521 · NHLBI · UNIVERSITY OF IOWA · PI WEI, SHUNGUANG · 2018 to 2022
$1.9M
High-Resolution Research UltrasoundS10OD019941 · OD · UNIVERSITY OF IOWA · PI WEISS, ROBERT M · 2015 to 2015
$298k
NHLBI NIH HHS R01 HL136149NHLBI NIH HHS R01 HL139521NHLBI NIH HHS R01 HL142935NIH HHS S10 OD019941
6 · The paper itself

Abstract

Activation of extracellular signal-regulated kinase 1 and 2 (ERK1/2) signaling in cardiovascular regulatory regions of the brain contributes to sympathetic excitation in myocardial infarction (MI)-induced heart failure (HF) by increasing brain renin-angiotensin system (RAS) activity, neuroinflammation, and endoplasmic reticulum (ER) stress. The mechanisms eliciting brain ERK1/2 signaling in HF are still poorly understood. We tested the involvement of the epidermal growth factor receptor (EGFR) which, upon activation, stimulates ERK1/2 activity. Adult male Sprague-Dawley rats received bilateral microinjections of a lentiviral vector encoding a small interfering RNA (siRNA) for EGFR, or a scrambled siRNA, into the hypothalamic paraventricular nucleus (PVN), a recognized source of sympathetic overactivity in HF. One week later, coronary artery ligation was performed to induce HF. Four weeks later, the EGFR siRNA-treated HF rats, compared with the scrambled siRNA-treated HF rats, had lower mRNA and protein levels of EGFR, lower levels of phosphorylated (p-) EGFR and p-ERK1/2 and lower mRNA levels of the inflammatory mediators TNF-α, IL-1β and cyclooxygenase-2, the RAS components angiotensin-converting enzyme and angiotensin II type 1a receptor and the ER stress markers BIP and ATF4 in the PVN. They also had lower plasma and urinary norepinephrine levels and improved peripheral manifestations of HF. Additional studies revealed that p-EGFR was increased in the PVN of HF rats, compared with sham-operated control rats. These results suggest that activation of EGFR in the PVN triggers ERK1/2 signaling, along with ER stress, neuroinflammation and RAS activity, in MI-induced HF. Brain EGFR may be a novel target for therapeutic intervention in MI-induced HF.

Indexed as

Heart FailureParaventricular Hypothalamic NucleusAnimalsErbB ReceptorsGene SilencingMaleMitogen-Activated Protein Kinase 3RatsRats, Sprague-DawleySympathetic Nervous SystemErbB ReceptorsMitogen-Activated Protein Kinase 3brainendoplasmic reticulum stressneuroinflammationp44/42 mitogen-activated protein kinaserenin-angiotensin system

Identifiers

PMID33540053
PMCPMC8106624

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.